Season's Savings | ₹5/mo for 3 months

₹199/month after first 3 months. Renews automatically. Terms apply.
Zoetis Q3 2026 Earnings Analysis cover art

Zoetis Q3 2026 Earnings Analysis

Zoetis Q3 2026 Earnings Analysis

Listen for free

View show details
About this listen
More earnings analysis: https://betafinch.com
Groups: PHARMA (https://betafinch.com/groups/PHARMA)
──────────
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Zoetis, ticker ZTS, and their third quarter 2026 results, which came out this morning.

**JORDAN:** Lots to unpack here — derm wars, screwworms, and a guy named Jay on his very first earnings call. Should be fun.

**ALEX:** It will be. But first, our standard disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Good, now let's get into it.

**ALEX:** So Zoetis is the big animal health company — pet meds, livestock vaccines, diagnostics. Q3 revenue came in at $2.4 billion, down about 1% both reported and organically. That was basically in line with what management expected going in.

**JORDAN:** Adjusted EPS, though, actually ticked up 1% to $1.75, mostly thanks to a lower share count from buybacks, not operational strength. So it's a bit of financial engineering helping the bottom line while the top line stays soft.

**ALEX:** Right, and the U.S. segment was the weak spot — down 6% to $1.2 billion. International was actually the bright spot, up 4% to $1.1 billion, with livestock, parasiticides, and OA pain more than offsetting dermatology headwinds overseas.

**JORDAN:** And dermatology is really the story of this quarter. Key derm sales fell 16% globally to $396 million. In the U.S., Apoquel lost share to new competitors, though the chewable version is now half of Apoquel's volume, which shows some stickiness there.

**ALEX:** And Cytopoint actually held up better than expected — management said the new injectable competitor's impact was minimal so far, partly because that competitor has had supply issues.

**JORDAN:** Here's a stat that stuck with me: U.S. canine visits were down about 5%, pruritic — meaning itchy-skin — visits down 3%. So it's not just competition, it's genuinely softer clinic traffic. Pet owners are being more careful with spending.

**ALEX:** Which ties into something CEO Kristin Peck mentioned — vet service costs are up 50% since 2022, way outpacing general inflation. That's squeezing pet owners and changing behavior.

**JORDAN:** Right, and even the pet population mix is shifting — more cats, fewer dogs, because of housing costs affecting adoption. Dogs are more "medicalized," as they put it, so that mix shift actually weighs on demand for vet services overall.

**ALEX:** Now, the good news: management said their defensive playbook is working. They used targeted promotional spending — what they call "gross-to-net" investments rather than cutting list prices — to slow the bleeding. Derm share loss improved from 7 points lost in Q2 to just 4 points in Q3.

**JORDAN:** And in parasiticides, Simparica Trio held its U.S. share at 22.5%, still roughly double the next competitor, and they remain the leader in new puppy starts, which is a nice leading indicator for future sales.

**ALEX:** On the innovation front, there's real stuff coming. Long-acting Cytopoint is expected to get FDA approval in Q4, launching in the first half of 2027. Simparica Duo approval is now expected by year-end, ahead of schedule.

**JORDAN:** And don't skip over livestock — that segment grew 7% to $797 million, with strength in cattle, swine, poultry vaccines, and even fish vaccines in Norway. Global protein demand is just a steady tailwind there, offsetting the companion animal softness nicely. Diversification is really earning its keep this quarter.

**ALEX:** Diagnostics also grew double digits — 13% to $122 million — boosted by the VitalRADS and VPG acquisitions plus organic adoption of their point-of-care platforms.

**JORDAN:** Now let's talk guidance, because this is where it gets interesting. Zoetis narro

This episode includes AI-generated content.
adbl_web_anon_alc_button_suppression_t1
No reviews yet